Abstract:Background Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in the last 10 years, current regulatory-approved management approaches are limited to two therapies that prevent the progression of fibrosis. The drug development pipeline is long and there is an urgent need to accelerate this process. This manuscript introduces the concept and design of an innovative research approach to drug development in fILD: a global Randomised Embedded Multifactorial Adaptive Platform in fILD (REMAP-ILD). Methods Description of the REMAP-ILD concept and design: the specific terminology, design characteristics (multifactorial, adaptive features, statistical approach), target population, interventions, outcomes, mission and values, and organisational structure. Results The target population will be adult patients with fILD, and the primary outcome will be a disease progression model incorporating forced vital capacity and mortality over 12 months. Responsive adaptive randomisation, prespecified thresholds for success and futility will be used to assess the effectiveness and safety of interventions. REMAP-ILD embraces the core values of diversity, equity, and inclusion for patients and researchers, and prioritises an open-science approach to data sharing and dissemination of results. Conclusion By using an innovative and efficient adaptive multi-interventional trial platform design, we aim to accelerate and improve care for patients with fILD. Through worldwide collaboration, novel analytical methodology and pragmatic trial delivery, REMAP-ILD aims to overcome major limitations associated with conventional randomised controlled trial approaches to rapidly improve the care of people living with fILD.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that in fibrotic interstitial lung diseases (fILDs), current treatment methods are limited and the drug development process is long, so this process needs to be accelerated. Specifically, the paper introduces the concept and design of REMAP - ILD (Randomised Embedded Multifactorial Adaptive Platform in fILD), which is an innovative research method aiming to accelerate and improve the treatment of fILD patients through a global randomised embedded multifactorial adaptive trial platform. ### Background Fibrotic interstitial lung diseases (fILDs) are a group of lung diseases associated with significant morbidity and mortality. Although the number of clinical trials has increased substantially in the past 10 years, currently, the management methods approved by regulators are limited to two therapies that prevent the fibrotic process. The drug development pipeline is long, and there is an urgent need to accelerate this process. ### Limitations of Traditional Clinical Trials Traditional randomised controlled trials (RCTs) usually evaluate a single research product, with a fixed sample size and study duration. These trials have multiple limitations, such as the need for a large fixed sample size, a fixed study duration, a lack of generalizability to the real - world population, equal chances for patients to receive control or active treatment, and a lack of motivation to design head - to - head trials of approved treatments. ### Design Features of REMAP - ILD The REMAP - ILD platform aims to overcome the limitations of traditional RCTs, and its main features include: - **Randomisation**: Patients are randomly assigned to all eligible and consented interventions. - **Embedded**: The study protocol is embedded in routine clinical care, reflecting standard practice and minimizing additional research procedures. - **Multifactorial Design**: Simultaneously test multiple interventions in multiple treatment areas, increasing the likelihood that patients will receive at least one active treatment rather than a control. - **Adaptability**: Use the information obtained during the trial to adjust the progress of the study according to preset procedures, such as the randomisation algorithm to determine randomisation weights and the stopping rules to define early success or ineffectiveness. - **Platform**: Establish a permanent infrastructure with the goal of generating a continuous learning system. ### Target Population The target population of REMAP - ILD is adult fILD patients, and the primary outcome is a disease progression model that combines forced vital capacity (FVC) and mortality within 12 months. ### Adaptive Features REMAP - ILD uses response - adaptive randomisation (RAR) to centrally recruit therapies that appear beneficial while minimizing resource use and risks to participants. In addition, it may also terminate a factor or area according to preset success or ineffectiveness thresholds. ### Patient Recruitment and Retention REMAP - ILD usually has broad eligibility criteria and simple study procedures, maximizing patient recruitment while retaining the ability to test treatment effect heterogeneity in the preset stratification. Embedding the trial in routine clinical practice reduces additional study visits and increases the likelihood of participation by patients living in remote areas. ### Data Analysis REMAP - ILD includes frequent preset adaptive analyses, using Bayesian statistical methods to make preset protocol changes during the trial based on cumulative data, including evaluating differential treatment effects within preset stratifications, evaluating preset intervention - intervention interactions, and testing multiple interventions. ### Mission and Values REMAP - ILD is an international collaborative network aiming to test treatment options for fILD patients quickly and efficiently, especially therapies suitable for repurposing. The core values of the platform include diversity, equity, and inclusion (DEI), and it gives priority to open - science data sharing and result dissemination. ### Conclusion By using an innovative and efficient adaptive multi - intervention trial platform design, REMAP - ILD aims to accelerate and improve the care of fILD patients. Through global cooperation, novel analytical methods, and pragmatic trial delivery, REMAP - ILD aims to overcome the main limitations of traditional randomised controlled trials and rapidly improve the quality of life of fILD patients.

Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

Immune mechanisms in fibrotic interstitial lung disease

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Protocol and research program of the European registry and biobank for interstitial lung diseases (eurILDreg)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Challenges for Clinical Drug Development in Pulmonary Fibrosis

A roadmap to precision treatments for familial pulmonary fibrosis

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

The dawn of precision medicine in fibrotic interstitial lung disease

The evolving pharmacotherapy of pulmonary fibrosis

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE

Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells